nach oben

vorheriger Artikel ÖGARI Ethik-Manifest für eine menschlichere Med...

nächster Artikel Einzelfallbericht über abweichende Pflegemaßnah...

Tipp

Ketamin: Einsatz bei chronischen Schmerzen und Depression

Zeitschrift:: Wiener Medizinische Wochenschrift > Ausgabe 15-16/2019

Autoren:: Dr. Wolfgang Jaksch, MSc Prim. Univ.-Prof. Dr. Rudolf Likar, Prim. Ao.Univ.-Prof. Dr. Martin Aigner

» Zum Volltext PDF-Version jetzt herunterladen

Wichtige Hinweise

Hinweis des Verlags

Der Verlag bleibt in Hinblick auf geografische Zuordnungen und Gebietsbezeichnungen in veröffentlichten Karten und Institutsadressen neutral.

Zusammenfassung

Obwohl Ketamin seit langem bekannt und im klinischen Einsatz ist, bleiben nach wie vor Fragen rund um die vielfältigen möglichen Anwendungsfelder als Anästhetikum und Analgetikum offen. Diese betreffen nicht das klassische Einsatzgebiet in der Notfallmedizin und Anästhesie, sondern auch potentielle, neue Indikationen, in denen Ketamin in niedrigen, subanästhetischen Dosierungen zum Einsatz kommt. Der Wirkmechanismus am NMDA-Rezeptor unterscheidet Ketamin deutlich von allen anderen Analgetika. Mögliche Einsatzgebiete sind Prävention chronischer postoperativer Schmerzen sowie die Behandlung neuropathischer Schmerzen. Mit der Behandlung der refraktären Depression könnte sich Ketamin auch in einem gänzlich neuen Feld etablieren.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Jetzt informieren

Annetta MG, Iemma D, Garisto C, et al. Ketamine: new indications for an old drug. Curr Drug Targets. 2005;6:789–94. PubMedPubMedCentral

Li L, Vlisides PE. Ketamine: 50 years of modulating the mind. Front Hum Neurosci. 2016;10:612. PubMedPubMedCentral

Peltoniemi MA, Hagelberg NM, Olkkola KT, et al. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55(9):1059–77. PubMedPubMedCentral

Schoevers RA, Chaves TV, Balukova SM, et al. Oral ketamine for the treatment of pain and treatment-resistant depression. Br J Psychiatry. 2016;208(2):108–13. PubMedPubMedCentral

Fanta S, Kinnunen M, Backman JT, et al. Population pharmacokinetics of S‑ketamine and norketamine in healthy volunteers after intravenous and oral dosing. Eur J Clin Pharmacol. 2015;71:441–7. PubMedPubMedCentral

Chong C, Schug SA, Page-Sharp M, et al. Development of a sublingual/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study. Clin Drug Investig. 2009;29:217–24.

Christensen K, Rogers E, Green GA, et al. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain. 2007;9:183–92.

Pelissier T, Laurido C, Kramer V, et al. Antinociceptive interactions of ketamine with morphine or methadone in mononeuro-pathic rats. Eur J Pharmacol. 2003;477:23–8. PubMedPubMedCentral

Sleigh J, Harvey M, Voss L, et al. Ketamine—More mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care. 2014;4:76–81.

10.

Salvadore G, Singh JB. Ketamine as a fast acting antidepressant: current knowledge and open questions. CNS Neurosci Ther. 2013;19(6):428–36. PubMedPubMedCentral

11.

Likar R, Jaksch W, Aigmüller T, et al. Interdisziplinäres Positionspapier „Perioperatives Schmerzmanagement“. Schmerz. 2017;31(5):463–82. PubMedPubMedCentral

12.

Benrath J, Brechtel C, Stark J, et al. Low dose of S(+)-ketamine prevents long-term potentiation in pain pathways under strong opioid analgesia in the rat spinal cord in vivo. Br J Anaesth. 2005;95:518–23. PubMedPubMedCentral

13.

Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000;93:409–17. PubMedPubMedCentral

14.

Liu XG, Sandkühler J. Long-term potentiation of C‑fiber-evoked potentials in the rat spinal dorsal horn is prevented by spinal N‑methyl-D-aspartic acid receptor blockage. Neurosci Lett. 1995;191:43–6. PubMedPubMedCentral

15.

Joly V, Richebe P, Guignard B, et al. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology. 2005;103(1):147–55. PubMedPubMedCentral

16.

Laskowski K, Stirling A, McKay WP, et al. A systematic review of intravenous ketamine for postoperative analgesia. Can J Anaesth. 2011;58(10):911–23. PubMedPubMedCentral

17.

Lavand’homme P, De Kock M, Waterloos H. Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery. Anesthesiology. 2005;103(4):813–20. PubMedPubMedCentral

18.

Himmelseher S, Durieux ME. Ketamine for perioperative pain management. Anesthesiology. 2005;102(1):211–20. PubMedPubMedCentral

19.

Jouguelet-Lacoste J, La Colla L, Schilling D, et al. The use of intravenous infusion or single dose of low-dose ketamine for postoperative analgesia: a review of the current literature. Pain Med. 2015;16:383–403. PubMedPubMedCentral

20.

Kissin I, Bright CA, Bradley EL Jr.. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? Anesth Analg. 2000;91:1483–8. PubMedPubMedCentral

21.

Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8(3):283–90. PubMedPubMedCentral

22.

Weinbroum AA. A single small dose of postoperative ketamine provides rapid and sustained improvement in morphine analgesia in the presence of morphine-resistant pain. Anesth Analg. 2003;96:789–95. PubMedPubMedCentral

23.

Lilius TO, Jokinen V, Neuvonen MS, et al. Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat. Br J Pharmacol. 2015;172(11):2799–813. PubMedPubMedCentral

24.

Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006;367:1618–25. PubMedPubMedCentral

25.

Schug SA, Pogatzki-Zahn EM. Chronic pain after surgery or injury. Pain 19(1):1–5.

26.

McNicol ED, Schumann R, Haroutounian S. A systematic review and meta-analysis of ketamine for the prevention of persistent post-surgical pain. Acta Anaesthesiol Scand. 2014;58:1199–213. PubMedPubMedCentral

27.

Hu J, Liao Q, Zhang F, et al. Chronic postthoracotomy pain and perioperative ketamine infusion. J Pain Palliat Care Pharmacother. 2014;28:117–21. PubMedPubMedCentral

28.

Tena B, Gomar C, Rios J. Perioperative epidural or intravenous ketamine does not improve the effectiveness of thoracic epidural analgesia for acute and chronic pain after thoracotomy. Clin J Pain. 2014;30:490–500. PubMedPubMedCentral

29.

Petrenko AB, Yamakura T, Baba H, et al. The role of N‑methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg. 2003;97:1108–16. PubMedPubMedCentral

30.

Niesters M, Khalili-Mahani N, Martini C, et al. Effect of subanesthetic ketamine on intrinsic functional brain connectivity: a placebo controlled functional magnetic resonance imaging study in healthy volunteers. Anesthesiology. 2012;117:868–77. PubMedPubMedCentral

31.

Niesters M, Aarts L, Sarton E, et al. Influence of ketamine and morphine on descending pain modulation in chronic pain patients: a randomized placebo controlled cross-over study. Br J Anaesth. 2013;110(6):1010–6. PubMedPubMedCentral

32.

Rigo FK, Trevisan G, Godoy MC, et al. Management of neuropathic chronic pain with methadone combined with ketamine: a randomized, double blind, active-controlled clinical trial. Pain Physician. 2017;20:207–15. PubMedPubMedCentral

33.

Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357–67. PubMedPubMedCentral

34.

Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145:304–11. PubMedPubMedCentral

35.

Lauritsen C, Mazuera S, Lipton RB, et al. Intravenous ketamine for subacute treatment of refractory chronic migraine: a case series. J Headache Pain. 2016;17:106. PubMedPubMedCentral

36.

Pomeroy JL, Marmura MJ, Nahas SJ, et al. Ketamine infusions for treatment refractory headache. Headache. 2017;57(2):276–82. PubMedPubMedCentral

37.

Zech DF, Grond S, Lynch J, et al. Validation of world health organization guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63(1):65–76. PubMedPubMedCentral

38.

Finkel JC, Pestieau SR, Quezado ZMN. Ketamine as an adjuvant for treatment of cancer pain in children and adolescents. J Pain. 2007;8(6):515–21. PubMedPubMedCentral

39.

Hardy J, Quinn S, Fazekas B, et al. Randomized, double-blind, placebo-controlled study to assess the efficacy and toxicity of subcutaneous ketamine in the management of cancer pain. J Clin Oncol. 2012;30(29):3611–7. PubMedPubMedCentral

40.

Zgaia AO, Irimie A, Sandesc D, et al. The role of ketamine in the treatment of chronic cancer pain. Clujul Med. 2015;88(4):457–61. PubMedPubMedCentral

41.

Ripamonti CI, Santini D, Maranzano E, et al. ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23(Suppl 7):vii139–vii54. PubMedPubMedCentral

42.

Bell RF, Jaksch W, Kalso EA. Interpreting the evidence: reply to Spruyt et al. J Pain Symptom Manage. 2014;47(4):e2–e4. PubMedPubMedCentral

43.

Gewandter JS, Mohile SG, Heckler CE, et al. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a university of rochester CCOP study of 462 cancer survivors. Support Care Cancer. 2014;22(7):1807–14. PubMedPubMedCentral

44.

Naughton M, Clarke G, O’Leary OF, et al. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord. 2014;156:24–35. PubMedPubMedCentral

45.

Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170:1134–42. PubMedPubMedCentral

46.

Swiatek KM, Jordan K, Coffman J. New use for an old drug: oral ketamine for treatment-resistant depression. BMJ Case Rep. 2016;3:2016.

47.

Irwin SA, Iglewicz A, Nelesen RA, et al. Daily oral Ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial. J Palliat Med. 2013;16(8):958–65. PubMedPubMedCentral

48.

Lally N, Nugent AC, Luckenbaugh DA, et al. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469. PubMedPubMedCentral

49.

Lally N, Nugent AC, Luckenbaugh DA, et al. Neural correlates of change in major depressive disorder anhedonia following open-label ketamine. J Psychopharmacol. 2015;29(5):596–607. PubMedPubMedCentral

50.

McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med. 2015;45(4):693–704. PubMedPubMedCentral

51.

Bobo WV, Vande Voort JL, Croarkin PE, et al. Ketamine for treatment-resistant unipolar and bipolar major depression: critical review and implications for clinical practice. Depress Anxiety. 2016;33(8):698–710. PubMedPubMedCentral

52.

Wilkinson ST, Sanacora G. Considerations on the off-label use of ketamine as a treatment for mood disorders. JAMA. 2017;318(9):793–4. PubMedPubMedCentral

53.

Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405. PubMedPubMedCentral

54.

Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013;74(4):250–6. PubMedPubMedCentral

55.

Singh, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816–26. PubMedPubMedCentral

56.

Fachinformation Ketanest®, Stand 06 (2017)

57.

Wang X, Ding X, Tong Y, et al. Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials. J Anesth. 2014;28(6):821–7. PubMedPubMedCentral

58.

Larsen R. Anästhesie. München, Jena: Elsevier, Urban & Fischer; 2010.

59.

Sinner B, Graf BM. Ketamine. Handb Exp Pharmacol. 2008;182:313–33.

60.

Thiel H, Roewer N. Anästhesiologische Pharmakotherapie: von den Grundlagen der Pharmakologie zur Medikamentenpraxis. Stuttgart, New York: Thieme; 2009.

61.

Tsai TH, Cha TL, Lin TT, et al. Ketamin-associated bladder dysfunction. Int J Urol. 2009;16:826–9. PubMedPubMedCentral

62.

Wood D, Cottrell A, Baker SC, Southgate J, et al. Recreational ketamine: from pleasure to pain. BJU Int. 2011;107(12):1881–4. PubMedPubMedCentral

63.

Jansen KLR. A review of the nonmedical use of ketamine: use, users and consequences. J Psychoactive Drugs. 2000;32(4):419–33. PubMedPubMedCentral

Titel: Ketamin: Einsatz bei chronischen Schmerzen und Depression
Autoren:: Dr. Wolfgang Jaksch
MSc Prim. Univ.-Prof. Dr. Rudolf Likar
Prim. Ao.Univ.-Prof. Dr. Martin Aigner
Publikationsdatum: 12.04.2019
DOI: https://doi.org/10.1007/s10354-019-0695-x
Verlag: Springer Vienna
Zeitschrift: Wiener Medizinische Wochenschrift
Ausgabe 15-16/2019
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Hinweis des Verlags

Zusammenfassung

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Weitere Artikel der Ausgabe 15-16/2019

Palliative Viszeralchirurgie bei maligner Dünndarmobstruktion nach kolorektalem Karzinom

Einzelfallbericht über abweichende Pflegemaßnahmen eines PICC-Katheters bei einem Palliativpatienten

Prof. Dr. Gerhart Hitzenberger zum 90. Geburtstag

Eine retrospektive Studie über den Einfluss einer Notfallinformation auf den Sterbeort von Palliativpatienten

ÖGARI Ethik-Manifest für eine menschlichere Medizin

Frau Doktor, wie lange noch?